{"pub": "wsj", "url": "https://marketwatch.com/story/acadia-pharmaceuticals-stock-rockets-after-late-stage-trial-of-pimavanserin-mets-primary-endpoint-2019-09-09?mod=rsswn", "downloaded_at": "2019-09-09 11:45:57.482540+00:00", "title": "Acadia Pharmaceuticals stock rockets after late-stage trial of pimavanserin mets primary endpoint", "language": "en", "text": "Shares of Acadia Pharmaceuticals Inc. ACAD, -2.94% rocketed 87% toward a 4-year high in premarket trading Monday, after the biopharmaceutical company said a phase 3 trial of its treatment for dementia-related psychosis met its primary endpoint. The company said pimavanserin achieved \"robust statistical superiority\" over placebo, with longer time to relapse of psychosis with pimavanserin compared with placebo. Acadia said the study will be stopped early based on the study's findings. The company plans to meet with the Food and Drug Administration regarding a supplemental new drug application (NDA) submission in 2020. The stock, on track to open at the highest price seen during regular-session hours since August 2015, has run up 47.2% year to date through Friday, while the iShares Nasdaq Biotechnology ETF IBB, -0.15% has gained 6.0% and the S&P 500 SPX, +0.09% has advanced 18.8%.", "description": "Shares of Acadia Pharmaceuticals Inc. rocketed 87% toward a 4-year high in premarket trading Monday, after the biopharmaceutical company said a phase 3 trial...", "authors": ["Tomi Kilgore", "Reporter"], "top_image": "https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png", "published_at": "2019-09-09"}